Viracta Therapeutics (NASDAQ:VIRX) Given “Neutral” Rating at Rodman & Renshaw

Rodman & Renshaw reiterated their neutral rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $0.25 price objective on the stock, down from their previous price objective of $3.50.

Separately, Royal Bank of Canada reduced their price target on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.05.

Viracta Therapeutics Trading Down 32.5 %

Shares of VIRX opened at $0.16 on Friday. The company’s 50-day moving average price is $0.19 and its 200 day moving average price is $0.31. Viracta Therapeutics has a 12-month low of $0.13 and a 12-month high of $1.31. The firm has a market cap of $6.36 million, a P/E ratio of -0.15 and a beta of 0.67.

Hedge Funds Weigh In On Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.